Michael S Rosenzweig

US Patent:

6440734, Aug 27, 2002

Filed:

Jun 7, 2000

Appl. No.:

09/509379

Inventors:

Mark J. Pykett - Newton MA
Michael Rosenzweig - Boston MA
Richard B. Kaplan - Beverly Hills CA

Assignee:

Cytomatrix, LLC - Woburn MA

International Classification:

C12N 502

US Classification:

435372, 435402, 4352891

Abstract:

The invention pertains to methods and devices for the long term, in vitro culture of hematopoietic progenitor cells in the absence of exogenously added hematopoietic growth factors, improved methods for the introduction of foreign genetic material into cells of hematopoietic origin, and to apparatus for performing these methods. The hematopoietic progenitor cells are cultured on a three-dimensional porous biomaterial. The three-dimensional porous biomaterial enhances hematopoietic progenitor cell survival and leads to an expansion of progenitor cell numbers and/or functionality, while maintaining progenitor cell pluripotency in the absence of exogenous growth factors. In addition, the three-dimensional porous biomaterial supports high level transduction on cells cultured upon such environment.

US Patent:

6548299, Apr 15, 2003

Filed:

May 18, 2000

Appl. No.:

09/574749

Inventors:

Mark J. Pykett - Newton MA 02165
Michael Rosenzweig - Boston MA 02116
David T. Scadden - Weston MA 02498
Mark C. Poznansky - Charlestown MA 02129

International Classification:

C12N 506

US Classification:

435377, 435363, 435372, 4353723, 435373, 435395, 435402, 435352, 435 355, 623 16

Abstract:

The invention relates to a method for lymphoid tissue-specific cell production from hematopoietic progenitor cells in unique, three-dimensional culture devices, in the presence of lymphoreticular stromal cells and in the absence of exogenously added growth factors. The resulting differentiated progeny. The lymphoid tissue-specific cells may be isolated at any sequential stage of differentiation and further expanded. The lymphoid tissue-specific cells also may be genetically altered at any stage of the process.

US Patent:

6645489, Nov 11, 2003

Filed:

May 10, 2002

Appl. No.:

10/143540

Inventors:

Mark J. Pykett - Boxford MA
Michael Rosenzweig - Boston MA
Richard B. Kaplan - Beverly Hills CA

Assignee:

Cytomatrix, LLC - Woburn MA

International Classification:

C12N 508

US Classification:

424 937, 435372, 435402, 4352891

Abstract:

The invention pertains to methods and devices for the long term, in vitroculture of hematopoietic progenitor cells in the absence of exogenously added hematopoietic growth factors, improved methods for the introduction of foreign genetic material into cells of hematopoietic origin, and to apparatus for performing these methods. The hematopoietic progenitor cells are cultured on a three-dimensional porous biomaterial. The three-dimensional porous biomaterial enhances hematopoietic progenitor cell survival and leads to an expansion of progenitor cell numbers and/or functionality, while maintaining progenitor cell pluripotency in the absence of exogenous growth factors. In addition, the three-dimensional porous biomaterial supports high level transduction on cells cultured upon such environment.

US Patent:

7067316, Jun 27, 2006

Filed:

Nov 10, 2003

Appl. No.:

10/705720

Inventors:

Mark J. Pykett - Boxford MA, US
Michael Rosenzweig - Boston MA, US
Richard B. Kaplan - Beverly Hills CA, US

Assignee:

Cytomatrix, LLC - Woburn MA

International Classification:

C12N 5/02

US Classification:

435402, 435372

Abstract:

The invention pertains to methods and devices for the long term, in vitroculture of hematopoietic progenitor cells in the absence of exogenously added hematopoietic growth factors, improved methods for the introduction of foreign genetic material into cells of hematopoietic origin, and to apparatus for performing these methods. The hematopoietic progenitor cells are cultured on a three-dimensional porous biomaterial. The three-dimensional porous biomaterial enhances hematopoietic progenitor cell survival and leads to an expansion of progenitor cell numbers and/or functionality, while maintaining progenitor cell pluripotency in the absence of exogenous growth factors. In addition, the three-dimensional porous biomaterial supports high level transduction on cells cultured upon such environment.

US Patent:

7192769, Mar 20, 2007

Filed:

May 31, 2002

Appl. No.:

10/161097

Inventors:

Mark J. Pykett - Boxford MA, US
Michael Rosenzweig - Boston MA, US
David T. Scadden - Weston MA, US
Mark C. Poznansky - Charlestown MA, US

Assignee:

Cytomatrix, LLC - Chelmsford MA

International Classification:

C12N 5/06

US Classification:

435373, 435377, 435382, 435395, 435399, 4353723

Abstract:

The invention relates to a method for lymphoid tissue-specific cell production from hematopoietic progenitor cells in unique, three-dimensional culture devices, in the presence of antigen presenting cells and lymphoreticular stromal cells, and in the absence of exogenously added growth factors. The resulting lymphoid tissue-specific cells may be isolated at any sequential stage of differentiation and further expanded. The lymphoid tissue-specific cells also may be genetically altered at any stage of the process.

US Patent:

7277722, Oct 2, 2007

Filed:

Jun 27, 2001

Appl. No.:

09/892681

Inventors:

Michael D. Rosenzweig - Hopkinton MA, US

Assignee:

Intel Corporation - Santa Clara CA

International Classification:

H04M 1/00
H04B 1/10

US Classification:

4555501, 455296

Abstract:

A way of reducing undesirable audio signals is provided. A portable device is provided that comprises a sensor to sense an audio signal and a control unit that is communicatively coupled to the sensor. The control unit is provided to receive a first audio signal from a storage unit and to generate a second audio signal based on at least a portion of the sensed audio signal to reduce an undesirable audio signal. The control unit is further provided to combine the first audio signal and the second audio signal and to provide the combined signal through a speaker.

US Patent:

7812135, Oct 12, 2010

Filed:

Mar 27, 2006

Appl. No.:

11/389880

Inventors:

L. Mary Smith - Dedham MA, US
Grazyna Szymanska - Dedham MA, US
Paul Ponath - San Francisco CA, US
Michael Rosenzweig - Boston MA, US
Jose F. Ponte - South Boston MA, US

Assignee:

TOLERRX, Inc. - Cambridge MA

International Classification:

C07K 16/00
C12P 21/08
A61K 39/395

US Classification:

5303881, 5303871, 5303873, 53038815, 53038822, 4241301

Abstract:

The present invention provides binding molecules that specifically bind to GITR, e. g. , human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e. g. , CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.

US Patent:

8388967, Mar 5, 2013

Filed:

Apr 2, 2010

Appl. No.:

12/753402

Inventors:

L. Mary Smith - Dedham MA, US
Grazyna Szymanska - Dedham MA, US
Paul Ponath - San Francisco CA, US
Michael Rosenzweig - Boston MA, US
Jose F. Ponte - South Boston MA, US

Assignee:

GITR, Inc. - Cambridge MA

International Classification:

A61K 39/395
A61K 39/00

US Classification:

4241431, 4241301, 4241331

Abstract:

The present invention provides binding molecules that specifically bind to GITR, e. g. , human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e. g. , CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.